Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals shared a post on X:
“FDA approves Zynyz® (retifanlimab-dlwr)
-
First and only approved 1st-line immunotherapy for advanced SCAC (anal cancer) in the U.S.Mechanism:Retifanlimab is a PD-1 inhibitor, restoring T-cell–mediated anti-tumor immunity in HPV-driven tumors.Backed by POD1UM-303 / InterAACT2
-
PFS: 9.3 vs 7.4 mo
-
OS: +6.2 mo | p = 0.0273
-
37% ↓ risk of progression or death
-
Combo: Zynyz + carbo/pacli
-
Also approved as monotherapy post platinumA big step forward in GI immunotherapy!”
